Britain and America have forged a important trade agreement that will ensure no import taxes on UK medicine products entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to raise funding on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these key products will remain at nothing for a duration of three years.
This agreement comes after recent warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases floated up to one hundred percent.
"This agreement with the UK strengthens the international landscape for innovative medicines and brings much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Drugs represent one of the Britain's biggest exports to the United States, which is easily the biggest buyer for major UK drugmakers.
Export figures reveal that in the 12 months leading up to September, the UK shipped medicines worth over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that period.
"This deal safeguards employment, boosts funding and sets the stage for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The pact includes several notable changes from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Last year, repayments topped twenty percent.
Recent Tensions
The deal follows a ongoing dispute between the drug companies and the British authorities over medicine costs and approval rates.
This friction were intensified by claims that American patients were charged significantly more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or scrapped, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the last ten years.
